GleamWall
中文EN

OCGN Ocugen, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1372299 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.3%
TTM net income YoY-24.7%
TTM EPS YoY-11.2%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,483.9%
Net margin-1,605.2%
FCF margin-1,334.3%
EBITDA margin-1,430.1%

Returns

ROE-660.0%
ROA-118.1%
ROIC (approx.)-1,221.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets89.8%
Debt / equity5.03x
Current ratio1.86x
Interest coverage-12.62x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue3.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.95M$1.49M$1.53M-$193,000$1.75M$1.37M$1.48M$764,000
R&D expense$12.50M$10.69M$11.26M$10.67M$11.15M$8.40M$9.53M$8.29M
SG&A expense$7.20M$7.24M$8.12M$6.13M$8.23M$6.77M$6.45M$6.31M
Operating income-$17.75M-$16.44M-$17.84M-$17.00M-$17.62M-$13.79M-$14.50M-$13.84M
Interest expense$3.09M$4.48M$1.32M$1.33M$1.31M$1.28M$1.26M$601,000
Net income-$3.60M-$24.88M-$19.18M-$17.71M-$20.05M-$14.74M-$15.35M-$13.88M
EBITDA-$17.25M-$15.84M-$17.24M-$16.39M-$17.02M-$13.20M-$13.90M—
EPS (basic)-0.01-0.07-0.06—-0.07-0.05-0.05—
EPS (diluted)-0.01-0.07-0.06—-0.07-0.05-0.05—
Weighted avg. shares (diluted)339.21M338.68M327.54M—304.00M292.07M292.00M—
Balance sheet
Cash & equivalents$24.63M$100.05M$31.90M$18.57M$32.88M$27.01M$38.11M$58.82M
Short-term investments$59.62M——$0————
Current assets$91.43M$106.72M$38.55M$24.34M$37.64M$32.88M$43.96M$61.68M
PP&E, net$12.71M$13.35M$13.83M$14.39M$14.95M$15.45M$15.99M$16.55M
Total assets$108.06M$124.21M$56.91M$43.52M$57.60M$53.59M$64.46M$82.44M
Current liabilities$118.90M$133.08M$20.71M$23.04M$20.36M$17.99M$16.89M$21.59M
Short-term debt$35,000$20,000$5.00M$1.25M$0$0$0$1.33M
Long-term debt$1.74M$1.73M$24.19M$27.54M$28.40M$28.02M$27.67M$27.34M
Total debt$1.78M$1.75M$29.19M$28.79M$28.40M$28.02M$27.67M$28.67M
Total liabilities$125.74M$140.76M$51.10M$55.68M$54.06M$50.54M$48.55M$52.81M
Shareholders' equity-$17.68M-$16.56M$5.80M-$12.17M$3.53M$3.05M$15.91M$29.63M
Net debt-$22.85M-$98.30M-$2.71M$10.22M-$4.48M$1.01M-$10.44M-$30.15M
Shares outstanding339.31M339.04M338.32M312.38M312.32M292.19M292.03M291.37M
Cash flow statement
Operating cash flow-$15.74M-$12.20M-$21.79M-$13.96M-$12.92M-$10.73M-$19.36M-$10.36M
Capital expenditure$149,000$21,000$6,000$35,000$91,000$43,000$16,000$13,000
Free cash flow-$15.89M-$12.22M-$21.80M-$14.00M-$13.01M-$10.77M-$19.37M-$10.38M
Investing cash flow-$59.77M-$21,000-$6,000-$35,000-$86,000-$88,000-$102,000-$13,000
Financing cash flow$161,000$80.37M$34.98M$2,000$18.51M$61,000-$1.25M$30.17M
Depreciation & amortization$500,000$600,000$600,000$600,000$600,000$600,000$600,000—
Stock-based compensation$1.96M$1.83M$3.40M$2.00M$1.98M$1.84M$1.89M$1.88M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.